JANX-013

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameJANX-013

Drug Alias NameJANX-013JANX013

ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-PSMAAnti-CD28

TargetsProstate-Specific Membrane AntigenT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJanux Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesJanux Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A